Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

5-Amino-1MQ icon5-Amino-1MQSmall moleculeNo amino acid sequence. Icon reflects category theme only.

5-Amino-1MQ

Beginner tier: 50 mg, daily · 10w on / 6w off · community consensus

Weight LossResearch
~4-6 hours half-life (estimated)·Oral

Also known as: 5-Amino-1MQ, 5A1MQ, 5-amino-1-methylquinolinium

Four amino acids short of being a peptide, 5-Amino-1MQ is actually a quinolinium salt weighing just 159.19 g/mol. It blocks nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in the fat tissue of obese individuals. In diet-induced obese mice, subcutaneous dosing cut fat mass, shrank adipocytes, and improved glucose tolerance without reducing food intake (Babula et al.)[1]. A separate 2024 study flagged a 40% grip strength increase in aged mice (Dimet-Wiley et al.)[2]. Zero human trials exist. The community figured out oral capsules before the science caught up, though Babula 2024 confirmed poor oral bioavailability in rodents. Most users take 100 mg/day for 8 to 12 weeks targeting body composition.

What Is 5-Amino-1MQ?

5-Amino-1MQ (5-amino-1-methylquinolinium, MW 159.19 g/mol) is a synthetic NNMT inhibitor taken orally as a capsule. No human clinical trial has been completed. All efficacy data comes from rodent models, and that gap matters.

NNMT methylates nicotinamide using S-adenosylmethionine (SAM) as a donor. When the enzyme runs hot in obese fat tissue and liver, it drains two molecules the body needs: NAD+ precursors and SAM. Block NNMT, and both pools recover. NAD+ feeds into sirtuin activation, mitochondrial biogenesis, and fatty acid oxidation. SAM drives a polyamine cycling loop that burns ATP. Think of it as flipping a metabolic switch that makes fat cells waste energy on purpose.

Kraus and colleagues first identified NNMT as an obesity target in a 2014 Nature paper [3]. The University of Texas group then screened quinolinium-based inhibitors and landed on 5-Amino-1MQ for its selectivity; it doesn't hit related methyltransferases (Neelakantan et al.)[4]. A 2018 follow-up showed subcutaneous dosing cut body weight and fat mass in obese mice without changing food intake [5]. Babula's 2024 study in Diabetes, Obesity and Metabolism confirmed dose-dependent improvements in glucose tolerance, insulin sensitivity, and hepatic steatosis over 28 days [1].

Community use runs ahead of the science. Most users take 50 to 150 mg/day orally for 8 to 12 weeks, stacking with AOD-9604 or semaglutide. Reports on r/Peptides and AnabolicMinds describe gradual midsection fat loss and improved energy, but a meaningful non-responder rate persists. Babula 2024 confirmed poor oral bioavailability in rodents; the community's preferred route has no preclinical validation. That gap matters.

How 5-Amino-1MQ Works

NNMT sits at the intersection of two metabolic currencies: SAM (the body's primary methyl donor) and nicotinamide (a precursor for NAD+ biosynthesis). In obese individuals, NNMT is overexpressed in white adipose tissue and liver. It catalyzes a methyl transfer from SAM to nicotinamide. The products, 1-methylnicotinamide and S-adenosylhomocysteine, are metabolically inert. The result is a steady drain on both SAM and NAD+ pools.

5-Amino-1MQ blocks this reaction selectively. When NNMT can't methylate nicotinamide, intracellular nicotinamide accumulates. It feeds into the NAD+ salvage pathway via NAMPT. Rising NAD+ levels activate SIRT1 and other sirtuin-dependent pathways that drive mitochondrial biogenesis and fatty acid oxidation.

SAM levels rise simultaneously. Raised SAM increases H3K4 histone methylation, which upregulates ornithine decarboxylase (ODC) and SSAT expression. These enzymes drive polyamine flux, an energy-expensive futile cycle that burns ATP and raises total cellular energy expenditure.

The net effect is a two-pronged metabolic shift. Fat cells burn more through polyamine cycling and mitochondrial activity. New fat creation (lipogenesis) drops. Across multiple mouse studies, this occurred without changes in food intake. Neelakantan's 2018 study confirmed that subcutaneous 5-Amino-1MQ reduced body weight, white adipose tissue mass, and adipocyte size in diet-induced obese mice [5]. Babula's 2024 study replicated these improvements and added dose-dependent glucose tolerance and hepatic steatosis corrections over 28 days [1].

5-Amino-1MQ Benefits

  • 5-Amino-1MQ benefits center on NNMT inhibition and its downstream metabolic effects, though all efficacy data comes from animal models.
  • Inhibits NNMT activity, increasing intracellular NAD+ and SAM availability. These two substrates fuel everything from mitochondrial energy production to DNA repair and epigenetic regulation.
  • Reduces white adipose tissue mass and shrinks adipocyte size in diet-induced obese mice without suppressing food intake (Neelakantan et al.)[5]. Fat loss occurs through higher energy expenditure, not caloric restriction.
  • Improves insulin sensitivity and normalizes glucose tolerance in a dose-dependent manner. Babula's 2024 study tracked this across a 28-day protocol in DIO mice [1].
  • Lowers plasma cholesterol and triglyceride levels in preclinical models; also attenuates hepatic steatosis and reduces liver inflammation markers in the same study population.
  • Oral administration. No injections, no reconstitution, no bacteriostatic water. You take a capsule. That said, oral bioavailability was flagged as poor in the Babula 2024 rodent data, so the convenience comes with an absorption question mark.
  • A 2024 study spotted grip strength gains (roughly 40% increase) and exercise capacity improvements in aged mice (Dimet-Wiley et al.)[2]. The community picked up on this finding quickly; recovery and workout performance are now the second most-discussed benefit after fat loss.

5-Amino-1MQ: Science vs Community Consensus

Divergent
Scientific Evidence
Weak
Based on 6 key studies·Research only

NNMT inhibition reduces fat mass, improves glucose tolerance, and attenuates hepatic steatosis in diet-induced obese mice.

Dosing studied: ~10 mg/kg/day SC in DIO mice (Babula 2024, PMID 39161060); ~50 mg/kg SC in aged mice for muscle endpoints (Dimet-Wiley 2024, PMID 38969654). No validated human dose exists.
Read the evidence (key study, limitations)

A July 2024 study [2] also demonstrated grip strength (~40% increase) and exercise capacity gains in aged mice. No human clinical trials have been conducted.

Key Study

Babula et al., Diabetes Obes Metab 2024 (PMID 39161060): 28-day diet-induced obese mouse study; dose-dependent reductions in body weight, fat mass, glucose intolerance, and hepatic steatosis via subcutaneous 5-amino-1MQ.

Limitations

All evidence from rodent models; zero human clinical trials. Babula 2024 confirmed poor oral bioavailability in rodents: subcutaneous administration was required for efficacy. Community primarily uses oral capsules, a route with no animal or human efficacy validation. Allometric scaling from 10 mg/kg SC mouse dose does not produce community flat-dose oral protocols.

Community Experience
Weak
3.5/5
Based on small: fewer than 100 trackable posts across r/Peptides and AnabolicMinds.com

Used orally for fat loss, energy enhancement, and body composition over 8-12 weeks.

Community dosing: 50-150 mg/day oral (community reports; most common 100 mg/day; some users go to 200); a minority injects subcutaneously, with no consistent dose reported
Read the reports (what users report 4, common issues 5)

Results are inconsistent; a meaningful non-responder rate is reported at standard doses. Oral bioavailability is increasingly questioned after Babula 2024.

What users report (4)
  • Increased energy within 1-2 weeks of starting, often the first reported effect
  • Gradual fat loss particularly around midsection reported over 8-12 weeks
  • Reduced post-exercise muscle soreness and improved workout recovery
  • Mild secondary appetite reduction (not the primary mechanism)
Common issues (5)
  • Significant non-responder rate: many users report no fat loss at standard oral doses
  • Mild GI disturbance (nausea, loose stools) common in first 1-2 weeks
  • Headache and mild fatigue in week 1
  • Oral bioavailability concerns now supported by Babula 2024 rodent data
  • Dizziness and fatigue at doses above 150 mg/day
Science & Community Diverge

Science validates NNMT inhibition for fat loss and metabolic improvement but exclusively via subcutaneous administration in animal models. Community uses oral capsules: a route that Babula 2024 flagged as having poor bioavailability in rodents. Community flat oral doses (50-150 mg/day, some users 200) also bear no clear relationship to validated SC mg/kg doses in animals. Route, dose rationale, and mechanism of oral benefit are all unaligned with the scientific evidence base.

5-Amino-1MQ Dosage Guide

CommunityCommunity dosing consensus from peptide research communities
LevelDoseFrequency
Beginner50 mgDaily
Moderate100 mgDaily
Aggressive150 mgDaily
Note:

This isn't an injectable. You're taking a capsule. No vials, no bacteriostatic water, no syringes, no reconstitution math. The standard product is 60 capsules at 50 mg each.

Start at 50 mg/day for the first one to two weeks. If you tolerate it, bump to 100 mg (two capsules). That's the most common community dose. Some users go to 150 mg but side effect reports pick up past that point.

The estimated half-life sits around 4 to 6 hours. If you notice an energy dip by early afternoon, splitting your dose (50 mg morning, 50 mg around noon) is a common workaround. No data supports or refutes this; it's community logic based on the PK estimate.

Source quality matters more than most people realize. Avoid online marketplace listings. No COA accountability exists on those platforms. A current HPLC certificate of analysis with purity at or above 98% is the only record of what a batch contains. Underdosing in capsule fill weight is the primary reported quality failure.

Store at room temperature. Cool, dry, away from sunlight. Shelf life runs 12 to 24 months.

Cycling Protocol

On Period
10 weeks
Off Period
6 weeks

Most community protocols recommend 8-12 weeks on followed by 4-8 weeks off. The absence of long-term human safety data makes cycling a precautionary measure rather than an evidence-based one. Start at the lower dose (50 mg/day) for the first 1-2 weeks before increasing. No more than 3 cycles per year is a common recommendation.

Calculate your 5-Amino-1MQ dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

5-Amino-1MQ Protocols by Goal

beginnerCommunity10 weeks on, 4-8 weeks off. Maximum 3 cycles per year.
Tolerance week
Wk 1-2
50 mg · Once daily · Oral (capsule)
Maintenance
Wk 3-10
100 mg · Once daily · Oral (capsule)

Expected: Gradual, modest body fat reduction (particularly visceral/abdominal) and energy increase. Community reports are variable: do not expect rapid fat loss. Non-responder rate at this dose is notable.

Monitor: Baseline and end-of-cycle fasting glucose and lipid panel recommended. Check ALT/AST if cycling more than twice per year.

How to Use 5-Amino-1MQ

  1. 1
    Confirm your capsule strength

    Most products come as 50 mg capsules. Check the label and the certificate of analysis to verify fill accuracy.

  2. 2
    Step 2

    Take one 50 mg capsule by mouth each morning for the first one to two weeks. This is your tolerance window. Take with food if GI discomfort occurs.

  3. 3
    Step 3

    After tolerance is established, increase to 100 mg/day (two capsules). Take both in the morning, or split: 50 mg morning, 50 mg around noon.

  4. 4
    Step 4

    If moving to 150 mg/day (intermediate protocol), add a third capsule. Split as 100 mg morning plus 50 mg afternoon. Watch for fatigue or dizziness at this dose.

  5. 5
    Take at a consistent time each day

    Morning dosing aligns with daily metabolic activity.

  6. 6
    Step 6

    Store capsules at room temperature (15 to 25 degrees Celsius) in a dry place away from sunlight. Shelf life is 12 to 24 months.

  7. 7
    Run for 8 to 12 weeks, then take 4 to 8 weeks off

    Maximum three cycles per year.

  8. 8
    Step 8

    Get bloodwork (fasting glucose, lipids, ALT/AST) at baseline and end of cycle.

  9. 9
    Step 9

    No injection equipment, reconstitution, or syringe calculations needed. This is an oral compound. For those using the subcutaneous route (the only one validated in animal studies): no consistent community SC dose is reported. Reconstitute lyophilized powder with bacteriostatic water. Inject subcutaneously in abdominal fat using a 29 to 31 gauge insulin syringe. Rotate sites.

Alternative Routes

Oral (capsule)

50-150 mg/day flat dose (community reports; some users go to 200); no relationship to validated SC mg/kg animal doses

Poor oral bioavailability confirmed in rodent model (Babula 2024). All animal efficacy studies exclusively used subcutaneous delivery. Community continues oral use based on convenience and wide availability. Any benefit from oral dosing is mechanistically unclear.

Subcutaneous injection

Community SC use: no consistent dose reported; animal efficacy studies: ~10 mg/kg/day SC

The only route with preclinical efficacy data. Requires reconstitution (bacteriostatic water). Less common in community due to injection burden given widely available oral capsules. No bridging data links any human SC dose to the animal mg/kg doses.

5-Amino-1MQ Stacking Protocols

Works With

Avoid

Methotrexate / folate antagonists

NNMT inhibition alters SAM (S-adenosylmethionine) availability. Methotrexate inhibits dihydrofolate reductase and affects the one-carbon methylation cycle. Combined disruption of SAM/methylation balance is unpredictable and potentially harmful.

Do not combine
Insulin and oral hypoglycemics (sulfonylureas, SGLT2i)

NNMT inhibition improves insulin sensitivity in preclinical models. Combined use with exogenous insulin or insulin secretagogues could produce additive glucose-lowering and hypoglycemia risk.

Estimated Cost

Compounded
$143-$210 per 60 capsules × 50 mg (research-grade market range, April 2026). Per-capsule range: $2.38-$3.50. A standard 10-week cycle at 100 mg/day requires ~70 capsules (~1.2 bottles at 60 caps). Online marketplace listings are now present at variable pricing with unverified COAs.

Pricing updated 2026-04-09

5-Amino-1MQ Side Effects

No human safety data exists for 5-Amino-1MQ. Zero clinical trials. Zero formal adverse event reports. Everything below comes from mouse studies and fewer than 100 trackable community posts across Reddit and AnabolicMinds.

The most serious theoretical concern is methylation pathway disruption. NNMT plays a direct role in SAM metabolism, and SAM is the methyl donor for DNA methylation, histone modification, and neurotransmitter synthesis. Inhibiting NNMT raises SAM levels, which sounds positive in isolation. But chronically altering SAM/NAD+ balance could have downstream effects on epigenetic regulation, liver function, and hormonal pathways that no one has measured in humans. Babula's 2024 study ran for 28 days in mice [1]. What happens at 6 months or 12 months? The data doesn't exist.

NNMT is also implicated in tumor biology. Its role is context-dependent: inhibition could theoretically promote or suppress tumor growth depending on the cancer type. Anyone with active cancer or a history of cancer should treat this as a hard stop. Not a "consult your doctor" situation.

Liver effects are a valid concern. NNMT is highly expressed in hepatic tissue. The Babula study showed ALT/AST reductions in obese mice, but the effects of NNMT inhibition in human livers (healthy, fatty, or otherwise) are completely uncharacterized. Monitoring liver enzymes (ALT, AST) at baseline and mid-cycle is a reasonable precaution.

In preclinical mouse studies at standard research doses, no observable adverse effects were reported (Neelakantan et al.; Babula et al.)[5][1]. That's reassuring but limited. Mice aren't people, and research doses aren't community doses.

Community-reported side effects at 50 to 150 mg/day oral:

GI discomfort is the most common complaint. Nausea and loose stools show up in week one for a visible fraction of users. Taking capsules with food typically helps. Headaches during initiation appear in early reports too, alongside mild fatigue. Both tend to clear by end of week one.

At doses above 150 mg/day, users report dizziness and more persistent fatigue. The compound's estimated half-life of 4 to 6 hours means a single morning dose may not sustain levels. Energy crashes mid-afternoon are a reported pattern. Splitting the dose is the common workaround.

Pregnancy and breastfeeding are absolute contraindications. No reproductive safety data exists. The same applies to anyone under 18 and anyone taking methotrexate or folate antagonists, where NNMT inhibition could unpredictably alter SAM availability.

If GI symptoms persist beyond two weeks, stop. If liver enzyme readings climb on mid-cycle bloodwork, stop. If fatigue doesn't resolve after the first week despite dose reduction, stop. This is a research chemical with zero human trial safety data; conservative decision-making isn't optional.

Common Issues & Solutions

No effect at 50-100 mg/day oral: Poor oral bioavailability is confirmed in rodent models (Babula 2024). All animal efficacy studies use subcutaneous administration. Community non-responders often increase to 150-200 mg/day or switch to SC injection, the only validated delivery route in preclinical data (no consistent community SC dose is reported).

GI discomfort (nausea, loose stools): Reported commonly in week 1. Taking with a small meal typically resolves it. If symptoms persist beyond 14 days, discontinue and reassess.

Headache on initiation: Usually self-limiting within week 1. Ensure adequate hydration and electrolyte intake. Temporarily reduce to 50 mg/day if severe before re-escalating.

Energy crash mid-day: The ~4-6h estimated half-life means a single morning dose may not sustain levels throughout the day. Splitting the dose (morning + early afternoon) is a common community workaround: no data supports or refutes this optimization.

Inconsistent fat loss across users: Preclinical efficacy was demonstrated in diet-induced obese mice in caloric excess. Users in a deficit may experience different dynamics. Non-response may also reflect poor oral absorption: this is a structural limitation of the compound at community doses, not a user error.

Ask AI about this page

Ask AI for a second opinion on 5-Amino-1MQ dosing and side effects

Contraindications

  • Pregnancy or breastfeeding: no reproductive safety data exists for this compound
  • Children and adolescents under 18: not studied in any pediatric context
  • Liver disease or impaired hepatic function: NNMT is highly expressed in liver tissue and inhibition effects are unknown in compromised livers
  • Active cancer: NNMT has been implicated in tumor biology with context-dependent effects; inhibition could theoretically promote or suppress growth depending on cancer type
  • Individuals taking medications that affect methylation pathways (e.g., methotrexate, folate antagonists)
  • Known hypersensitivity to quinolinium compounds

Drug Interactions

  • NAD+ precursors (NMN, NR, niacin): 5-Amino-1MQ increases NAD+ through the salvage pathway; stacking with exogenous precursors may have additive effects but hasn't been studied
  • Metformin: both compounds affect energy metabolism through different mechanisms; combined effects on glucose handling are unpredictable without data
  • SIRT1 activators (resveratrol): since NNMT inhibition raises NAD+ and activates SIRT1, combining with direct SIRT1 activators could amplify downstream effects
  • Methylation-dependent drugs (methotrexate, azathioprine): NNMT inhibition alters SAM availability, which could theoretically affect the metabolism of drugs that depend on methyltransferase activity
  • Statins and lipid-lowering agents: additive cholesterol-lowering effects are possible given the lipid reductions observed in preclinical models
  • Insulin and oral hypoglycemics: NNMT inhibition improves insulin sensitivity in animal models; combined use could increase hypoglycemia risk

Product Quality

Recommended Monitoring

TestWhenTarget
Fasting glucose + fasting insulinBaseline before cycle start; end of cycleFasting glucose 70-100 mg/dL; fasting insulin 2-20 µIU/mL
Lipid panel (total cholesterol, LDL, HDL, triglycerides)Baseline and end of cycleNot listed
Liver enzymes (ALT, AST)Baseline, week 6, end of cycleALT <40 U/L; AST <40 U/L
Fasting glucose + fasting insulin

NNMT inhibition improves insulin sensitivity in preclinical models; combined use with hypoglycemic agents carries hypoglycemia risk. Establishes metabolic baseline.

Lipid panel (total cholesterol, LDL, HDL, triglycerides)

Preclinical data demonstrates significant cholesterol and triglyceride reductions in mice. Human lipid response is unstudied: monitor for unexpected shifts in either direction.

Liver enzymes (ALT, AST)

NNMT is highly expressed in liver tissue. Babula 2024 showed ALT/AST reductions in DIO mice, but hepatic effects of NNMT inhibition in healthy or metabolically varied humans are unknown. Chronic use risk is uncharacterized.

5-Amino-1MQ Before and After

Week 1

No visible changes expected. The compound begins inhibiting NNMT at the cellular level, increasing intracellular NAD+ and SAM. Some users report a subtle uptick in energy or slight GI adjustment. This is a calibration period: assess tolerance before increasing dose.

Weeks 2-3

Metabolic shifts are underway but still largely subclinical. Polyamine cycling and enhanced fatty acid oxidation should be active. Some users report improved energy levels and slightly better workout recovery. Body weight changes are typically minimal at this stage.

Weeks 4-6

This is where animal studies show measurable reductions in adipose tissue mass and adipocyte size. Users may begin noticing changes in body composition: particularly around the midsection. Improvements in fasting glucose and lipid panels may become detectable on bloodwork.

Weeks 7-10

Cumulative effects should be at their peak. In the 28-day mouse study, dose-dependent reductions in body weight, fat mass, and liver triglycerides were well-established by this equivalent timepoint. Users often report the most noticeable body composition changes during this window.

Post-cycle
weeks off

Discontinue use and allow NNMT activity to normalize. Metabolic benefits may persist for 1-2 weeks after the last dose as NAD+ and SAM levels gradually return to baseline. Maintain dietary and exercise habits established during the cycle. Wait 4-8 weeks before starting another round.

What to Expect

Week 1 (Tolerance establishment): NNMT inhibition kicks in at the cellular level. NAD+ and SAM concentrations begin shifting inside adipocytes. Don't expect anything visible yet. Some users pick up a subtle energy bump within the first few days. GI adjustment is common: mild nausea, loose stools, headache. These typically clear by day seven. This is the calibration window before increasing dose.

Weeks 2 to 3 (Metabolic shift initiation): Polyamine cycling and fatty acid oxidation should be running based on mouse PK timelines. Changes are subclinical. Users commonly report improved energy and better workout recovery. Scale weight probably hasn't moved. The internal machinery is working, but the mirror won't show it yet.

Weeks 4 to 6 (Early body composition changes): Animal studies show measurable reductions in fat mass and adipocyte size in this window. Users may start noticing midsection changes. Fasting glucose and lipid panels may move on bloodwork. Babula's 2024 DIO mouse data showed clear metabolic marker improvements in this equivalent timeframe [1]. Some community users plateau or report no change; that non-responder pattern is real.

Weeks 7 to 10 (Peak cumulative effect): The Babula 28-day study showed dose-dependent reductions in body weight, fat mass, and liver triglycerides by this equivalent timepoint. Most users who respond report their best body composition changes here. If you haven't seen movement by week 8, increasing dose or switching routes (oral to subcutaneous) is the community's go-to adjustment. No data validates either change in humans.

Post-cycle, weeks off (NNMT normalization): Stop dosing. NNMT activity returns to baseline. NAD+ and SAM levels normalize over one to two weeks. No rebound fat gain was documented in animal models after discontinuation. Keeping the diet and exercise habits you built during the cycle matters most for holding results. Wait 4 to 8 weeks before starting another round.

Detailed Timeline: Science vs Community

Week 1
Science

NNMT inhibition begins intracellularly. NAD+ and SAM levels start to shift. No measurable fat loss expected at this stage.

Community

Subtle energy increase noted by some users within days. GI adjustment (mild nausea, loose stools) is common. No visible body composition changes.

Weeks 2-3
Science

Polyamine cycling and enhanced fatty acid oxidation should be active based on mouse PK data. Adipocyte-level changes are occurring but not yet clinically measurable.

Community

Improved energy and workout recovery reported. Some users notice mild performance improvements. Scale weight changes still minimal.

Weeks 4-6
Science

Animal studies show measurable reductions in adipose tissue mass and adipocyte size in this window. Glucose and lipid improvements detectable on bloodwork in DIO mouse models.

Community

Most users begin noticing body composition changes, particularly around the midsection. Some report improvements in fasting glucose on labs. A subset report plateau or no change.

Weeks 7-10
Science

Babula 2024 28-day DIO mouse study showed dose-dependent fat mass, liver triglyceride reductions, and metabolic marker normalization well-established by this equivalent timepoint.

Community

Most noticeable body composition changes reported in this window. Some users plateau without additional dietary adjustment. Continued energy and recovery benefits.

Post-cycle (weeks off)
Science

NNMT activity returns to baseline. NAD+ and SAM levels normalize over 1-2 weeks. No rebound fat gain documented in animal models after discontinuation.

Community

Users report metabolic benefits persisting for 1-2 weeks after last dose. Maintaining diet and exercise habits during the off period is the primary determinant of sustaining results.

Pharmacokinetics

Half-Life
5h
Bioavailability
Oral: not formally determined in humans; adequate oral bioavailability demonstrated in mice with detectable levels in target tissues
Tmax
~1-2 hours (estimated from preclinical oral dosing)
Data Confidence
low

Source: Estimated from the 2024 pharmacokinetic characterization study in DIO mice (PMID 39161060). No human PK data exists. The compound showed adequate oral bioavailability in mice with tissue distribution to adipose and liver compartments.

Pharmacokinetics: Active Dose Over Time

t½ = ~4-6 hours (estimated oral)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Who Should Consider 5-Amino-1MQ

  • Adults researching non-injectable metabolic support compounds for body composition
  • Individuals interested in NNMT inhibition for stubborn adipose tissue
  • Researchers studying the NNMT-NAD+-SIRT1 axis in obesity and metabolic syndrome
  • People seeking oral alternatives to injectable fat-loss peptides like AOD-9604
  • Scientists investigating hepatic steatosis and fatty liver pathology interventions

Related Peptides

What Changed for 5-Amino-1MQ

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20266 Citations

References

  1. [1]Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction (Babula et al., Diabetes Obes Metab 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Nicotinamide N-methyltransferase inhibition mimics exercise-mediated improvements in muscle function in aged mice (Dimet-Wiley et al., Sci Rep 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity (Kraus et al., Nature 2014) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase (Neelakantan et al., J Med Chem 2017) (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]Selective and membrane-permeable small molecule inhibitors of NNMT reverse high fat diet-induced obesity in mice (Neelakantan et al., Biochem Pharmacol 2018) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Store capsules at room temperature (15-25°C) in a cool, dry place away from direct sunlight. Shelf life is typically 12-24 months when stored properly.
After Reconstitution
N/A: oral capsule formulation, no reconstitution required.
Temperature
15-25°C (59-77°F), room temperature

Frequently Asked Questions

5-Amino-1MQ is an oral NNMT (nicotinamide N-methyltransferase) inhibitor. NNMT converts active NAD+ into inactive methylnicotinamide in fat tissue. By blocking NNMT, the compound theoretically preserves NAD+ pools and shifts fat cells from storage toward oxidation. The mechanism is backed by cell culture and rodent data but zero published human trials.

Beginner: 50 mg oral daily. Moderate: 100 mg daily (two 50 mg capsules, together or split morning and noon). Aggressive: 150 mg daily. Dosing is entirely community-derived; no human pharmacokinetic study has been published. Most users take it with food to reduce GI irritation.

Community reports mention GI discomfort (nausea, loose stools), headache, and occasional insomnia. Safety data is extremely limited since no formal human trial has been completed. The compound has a safety grade of C due to the complete lack of human clinical data. Monitor liver function if running cycles beyond 4 weeks.

Mice fed a high-fat diet and treated with 5-Amino-1MQ showed reduced adiposity and improved metabolic markers. Nobody has replicated this in a controlled human study. Community results are mixed: some users report modest fat loss over 4-8 week cycles; others report no measurable change. Expectations should be calibrated to the evidence level.

No. 5-Amino-1MQ is taken by mouth and is not reconstituted with bacteriostatic water.